Ex­clu­sive: Trail­ing Karuna, Map­Light Ther­a­peu­tics aims to im­prove schiz­o­phre­nia, CNS drugs with $225M Se­ries C

Map­Light Ther­a­peu­tics has raised a $225 mil­lion round to en­ter Phase II clin­i­cal tri­als in schiz­o­phre­nia and Alzheimer’s dis­ease psy­chosis and run an on­go­ing mid-stage study for autism spec­trum dis­or­der, the com­pa­ny told End­points News.

The Se­ries C fi­nanc­ing gives the Bay Area biotech the chance to test whether its tablet can pig­gy­back off the suc­cess that Karuna Ther­a­peu­tics has seen with its schiz­o­phre­nia drug KarXT, which, if ap­proved next year, could be the first big ad­vance­ment for the brain dis­or­der in mul­ti­ple decades.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER